IFNG and psoriatic arthritis: The study discovered that over these years, there were fluctuations in the production of IFN-γ, with the lowest levels in the first dose and after four years of use, while the doses after one, two, and eight years were even larger than the initial one, and there were no differences between the production of this cytokine in the two TNF blockers evaluated, namely etanercept and adalimumab, or between the two diseases, rheumatoid and psoriatic arthritis.